These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23350342)

  • 1. [Etidronate and calcitonin to PTH (1-84) in postmenopausal osteoporosis].
    Rodríguez Rodríguez LP
    An R Acad Nac Med (Madr); 2011; 128(1):169-91; discussion 191-8. PubMed ID: 23350342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between studies and general practice].
    MMW Fortschr Med; 2006 Nov; 148(46):49. PubMed ID: 17615791
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of osteoporosis using the ADFR schedule (especially with parathyroid hormone and etidronate)].
    Ziegler R
    Internist (Berl); 1991 Feb; 32(2):76-9. PubMed ID: 1903362
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease.
    Arase Y; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Ikeda K; Kumada H
    J Med Virol; 2008 Jul; 80(7):1302-7. PubMed ID: 18461628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of osteoporosis with parathyroid hormone].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2008 Jan; 128(1):39-41. PubMed ID: 18183056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fracture prevention in postmenopausal women.
    Mosekilde L; Vestergaard P; Langdahl B
    Clin Evid; 2006 Jun; (15):1543-60. PubMed ID: 16973058
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Indications and limitations of non-hormonal treatments of osteoporosis].
    Avouac B
    Rev Fr Gynecol Obstet; 1993; 88(7-9):419-23. PubMed ID: 8235256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
    Borgström F; Ström O; Marin F; Kutahov A; Ljunggren O
    J Med Econ; 2010; 13(3):381-92. PubMed ID: 20604678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs for postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2008 Oct; 6(74):67-74; quiz 75-6. PubMed ID: 18800025
    [No Abstract]   [Full Text] [Related]  

  • 11. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
    Zikan V; Stepan JJ
    Bone; 2009 Apr; 44(4):634-8. PubMed ID: 19150421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials.
    Cardona JM; Pastor E
    Osteoporos Int; 1997; 7(3):165-74. PubMed ID: 9205627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis.
    Zhang L; Yang M; Liu D; Guo C; Li L; Yang G
    Exp Clin Endocrinol Diabetes; 2012 Jun; 120(6):361-6. PubMed ID: 22639400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
    Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
    N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.
    Zhang XZ; Wang B; Yang J; Xuan M; Song LG; Li H; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Shen J; Liu ZM; Li CJ; Wu TF; Tong XC; Jia Y
    Chin Med J (Engl); 2009 Dec; 122(24):2933-8. PubMed ID: 20137477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic strategies for osteoporosis].
    Chapurlat R; Delmas PD
    Ann Med Interne (Paris); 2000 Oct; 151(6):471-6. PubMed ID: 11104926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Morphologic study of iliac crest spongiosa in patients with osteoporosis treated according to the ADFR (activation, depression of resorption, formation, repeat the cycle) with parathyroid hormone and diphosphonates (Hannover PTH I study)].
    Delling G; Dreyer T; Hahn M; Vogel M; Rittinghaus EF; Hesch RD
    Z Orthop Ihre Grenzgeb; 1990; 128(1):1-5. PubMed ID: 2138378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
    Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
    Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Men also need bone protection].
    MMW Fortschr Med; 2006 Nov; 148(46):48-9. PubMed ID: 17615790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.